vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Lion Group Holding Ltd (LGHL). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $13.3M, roughly 1.5× Lion Group Holding Ltd). Lion Group Holding Ltd runs the higher net margin — -0.4% vs -177.4%, a 177.0% gap on every dollar of revenue.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

LION is a Canadian electric vehicle manufacturer headquartered in Saint-Jérôme, Quebec. Founded in 2011 as Lion Bus, the company is primarily known for its production of yellow school buses, of which it was the first to mass produce as a fully electric vehicle.

LAB vs LGHL — Head-to-Head

Bigger by revenue
LAB
LAB
1.5× larger
LAB
$19.6M
$13.3M
LGHL
Higher net margin
LGHL
LGHL
177.0% more per $
LGHL
-0.4%
-177.4%
LAB

Income Statement — Q3 FY2025 vs Q2 FY2024

Metric
LAB
LAB
LGHL
LGHL
Revenue
$19.6M
$13.3M
Net Profit
$-34.7M
$-53.7K
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
-177.4%
-0.4%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LGHL
LGHL
Q3 25
$19.6M
Q2 25
$21.8M
Q1 25
$40.8M
Q3 24
$22.1M
Q2 24
$22.5M
$13.3M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
LAB
LAB
LGHL
LGHL
Q3 25
$-34.7M
Q2 25
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-45.7M
$-53.7K
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
LAB
LAB
LGHL
LGHL
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
LAB
LAB
LGHL
LGHL
Q3 25
-168.5%
Q2 25
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
LAB
LAB
LGHL
LGHL
Q3 25
-177.4%
Q2 25
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-203.3%
-0.4%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
LAB
LAB
LGHL
LGHL
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LGHL
LGHL
Cash + ST InvestmentsLiquidity on hand
$129.4M
$29.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$28.4M
Total Assets
$539.6M
$74.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LGHL
LGHL
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
$29.0M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
LAB
LAB
LGHL
LGHL
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
LAB
LAB
LGHL
LGHL
Q3 25
$399.7M
Q2 25
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$510.3M
$28.4M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
LAB
LAB
LGHL
LGHL
Q3 25
$539.6M
Q2 25
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$708.7M
$74.5M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
LAB
LAB
LGHL
LGHL
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LGHL
LGHL
Operating Cash FlowLast quarter
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LGHL
LGHL
Q3 25
$-22.2M
Q2 25
$-20.7M
Q1 25
$-30.3M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
LAB
LAB
LGHL
LGHL
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
LAB
LAB
LGHL
LGHL
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
LAB
LAB
LGHL
LGHL
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LGHL
LGHL

Trading gains$7.8M59%
Other$2.4M18%
Securities brokerage commissions and fees$1.7M13%
Market making commissions and fees$1.0M8%
Other income$380.2K3%

Related Comparisons